Chat with us, powered by LiveChat

Loading...

Computer-aided Drug Discovery Market Report

RA00159

Computer-aided Drug Discovery Market by Type (Structure-based Drug Design (SBDD), Ligand-based Drug Design (LBDD), Sequence-based Approaches), Therapeutic Area (Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes, and Others), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028

RA00159

Pages: 224

Jun 2021

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Computer-aided Drug Discovery Market

Global Computer-aided Drug Discovery Market Analysis

The global computer-aided drug discovery market is predicted to garner $7,914.2 million in the 20212028 timeframe, growing from $2,747.1 million in 2020 at a healthy CAGR of 15%.

Market Synopsis

Strategic alliances among market players, along with growing demand for drugs, is expected to accelerate the growth of the computer-aided drug discovery market.

However, lack of professional technicians and knowledge about computer-aided drug discovery is one of the growth-restricting factors for the market.

According to the regional analysis, the Asia-Pacific computer-aided drug discovery market is anticipated to grow during the review period due to increasing research activities in Asian countries.  

Computer-aided Drug Discovery Overview

Computer-aided drug discovery is the computational approach for modern discovery of drugs. It includes molecular modeling, rational drug design, molecular design, and computational chemistry. Also computer-aided drug discovery is cost effective and it can save a lot of time in drug discovery.

Impact Analysis of COVID-19 on the Global Computer-aided Drug Discovery Market

Though the novel coronavirus pandemic had a devastating effect on several industries, the computer-aided drug discovery market experienced a significant growth during this period. The market for computer-aided drug discovery has seen higher rate of growth owing to increased R&D activities among the scientists, researchers, and biotechnological and biopharmaceutical companies to restrict the spread of the coronavirus disease. Increasing transmutation rate of coronavirus has motivated the scientists across the world to discover an effective treatment or a drug against this deadly virus. Therefore, the importance of research and drug discovery has skyrocketed, thus driving the growth of the market.

In addition to this, several companies are helping the society to recover from the chaotic situation with their strategic plans and steps. For instance, BenevolentAI, a UK based developer of artificial intelligence and computational medicine technologies, announced in December 2020 that they are developing drugs on COVID-19 with the help of artificial intelligence and computer-aided drug discovery technology. The above-stated factors show that the pandemic may generate substantial investment opportunities in the market in the coming years.

Increasing Utilization of Artificial intelligence for Drug Discovery to Surge the Market Growth

The global computer-aided drug discovery industry is witnessing a massive growth mainly due to increase in the usage of artificial intelligence in drug discovery for drug screening, chemical synthesis, polypharmacology and to study the three-dimensional structure of molecules. Moreover, artificial intelligence has provided many opportunities to the companies to enter the market and use AI technology in the integration with computer aided drug discovery. For instance, Insilico Medicine, a global leader in artificial intelligence on June 2021 announced that they will release a fund of $255 million to biotechnology experts to continue their current therapeutic programs into human clinical trials, thereby driving the adoption of computer-aided drug discovery.  

There is increasing demand for rapid drug development for various diseases such as cancer which in turn is expected to drive the market of computer-aided drug discovery.  Key players working in computer-aided drug discovery market are following notable strategies such as product innovation along with strategic tie-ups in order to grow worldwide. For instance, in November 2020, Bristol Myers Squibb and Schrödinger, Inc. announced that they are in research collaboration to discover, commercialize, and develop therapeutics for multiple diseases. Also, Schrödinger is utilizing their highly advanced physics-based software that will allow the discovery of high-quality drugs. These types of initiatives from market leaders are also predicted to drive the growth of the market.

To know more about global computer-aided drug discovery market drivers, get in touch with our analysts here.

Lack of Technical Knowledge of Computer-aided Drug Discovery to Restrain the Market Growth

The computer-aided drug discovery is computational tool that requires highly skilled technicians and lack of knowledge is expected to restrain the growth of the global market during the forecast period. Also, lack of standardization for testing and validation of the results of drugs will limit the global market growth.        

Advancements in the Field of Computer-aided Drug Discovery in the Market to Create Massive Investment Opportunities

The global computer-aided drug discovery market is growing at a very fast pace due to increasing combination of different technologies pacing up the research activities and also providing accurate results in lesser time span. The computer-aided drug discovery (CADD) technology is also compounded by some latest emerging technologies like machine learning (ML) and artificial intelligence (AI) which drive the research programs in the biotechnological and pharmaceutical industries. These are major growth accelerating factors for the market.

Furthermore, many manufacturing companies have started spending a huge amount of their annual budget in technologies to discover new drugs for various chronic diseases. For instance, according to a news published on August 3, 2020, on Genetic Engineering & Biotechnology news, Arctoris, a U.K based biotechnological company, developed a drug discovery platform integrated with quantum computing and artificial intelligence that will provide the clients with on-demand access to a wide range of biochemical, molecular, and cell-based assays conducted entirely by robots. All these factors may further lead to lucrative market opportunities for key players in the upcoming years.

To know more about global computer-aided drug discovery market opportunities, get in touch with our analysts here.

Computer-aided Drug Discovery Market
By Type

Your browser does not support the canvas element.

Based on type, the market has been divided into structure-based drug design, Ligand-Based Drug Design and sequence-based approaches sub-segments of which structure-based drug design sub-segment is projected to generate the fastest growth and ligand-based sub-segment is projected to acquire a dominant market share.

Source: Research Dive Analysis

The structure-based drug design type sub-segment is predicted to be the fastest growing in the global market. The sub-segment is expected to register a revenue of $2,539.4 million during the forecast period. Structure-based drug design is the traditional way of drug discovery that uses NMR, cryo-EM, and X-ray crystallography for optimization and designing of compounds. Moreover, technological advancements along with growing demand for new drugs for various diseases are some elements surging the demand for structure-based drug design type of computer-aided drug discovery, in the global market, over the forecast period. For instance, Sosei Group Corporation, in February 2021 announced that they are in collaboration with Metrion Biosciences Limited; the main aim of the collaboration is to apply structure-based drug design and ion channels for the development of new drugs. These factors and strategic alliances by key companies may bolster the growth of segment during the forecast period.

The ligand-based drug design type sub-segment is predicted to have a dominant market share in the global market. The sub-segment is expected to register a revenue of $3,366.4 million during the forecast period. Ligand-based drug design is the approach which explains the relation of compound structure and their relative chemistry.  In addition to this, certain market leaders are emphasizing mainly on the technological innovations to fulfil the needs of organizations. For instance, China based Insilico Medicine announced that they are linking artificial intelligence, biology, and chemistry for discovering idiopathic pulmonary fibrosis ("IPF") with validation to human cells. Also, molecules are designed with the help of ligand-based drug design to study the properties of molecules. All such factors will enhance the computer-aided drug discovery market and it may accelerate the global market.

Computer-aided Drug Discovery Market
By Therapeutic Area

Your browser does not support the canvas element.

On the basis of therapeutic area, the market has been sub-segmented into Oncology, neurology, cardiovascular disease, respiratory disease, diabetes, and others. Among the mentioned sub-segments, the cardiovascular disease sub-segment is predicted to show the fastest growth and Oncology sub-segment will garner a dominant market share.

Source: Research Dive Analysis

The cardiovascular disease sub-segment of the global computer-aided drug discovery market is projected to have the fastest growth. It is also projected to surpass $1,368.6 million by 2028, with an increase from $454.1 million in 2020. This growth in the market can be attributed to increasing prevalence of heart diseases across the globe. Heart problems are the major cause of death across the globe. Treatment for cardiovascular diseases is very challenging due to various reasons such as inflammatory, immunological mechanisms, and neuroendocrine complications. Therefore, it is very important that during the development of CVD drugs, all the data be obtained and work monitored on every step.  All such elements may increase the demand for cardiovascular disease and further surge the market growth.

The oncology type sub-segment is predicted to have the dominant market share in the global market. The sub-segment is expected to register a revenue of $1,880.7 million during the forecast period. Oncology medicinal branch deals with treatment, prevention, and diagnosis of cancer.  There are different types of cancers and to understand the type of medication required for a particular cancer is a complex process. However despite detailed research, cancer treatment has been one of the major concerns across the globe because of the resistance to medication. Therefore, demand for cancer drugs that are efficient, cost-effective and successful is surging.  These key elements may accelerate the growth of segment during the forecast period. 

Computer-aided Drug Discovery Market
By Region

Your browser does not support the canvas element.

The computer-aided drug discovery market was investigated across North America, Europe, Asia-Pacific, and LAMEA.

Source: Research Dive Analysis

The Market for Computer-aided Drug Discovery in North America to be the Most Dominant

The North America computer-aided drug discovery market accounted $991.7 million in 2020 and is projected to register a revenue of $2,730.4 million by 2028. The extensive growth of the North America computer-aided drug discovery market is mainly driven by increasing research activities in institutes and hospitals have also initiated and advanced their research activities using computer aided drug discovery in the field of cancer. For instance, according to an article published on the official site of The Ohio State University, on June 04, 2021, the university was the first academic medical center in the country to use a new computer-aided system for the screening of colonoscopy in patients undergoing testing at the hospital. These factors will ultimately drive the demand in the computer-aided drug discovery market across the region.

The Market for Computer-aided Drug Discovery in Asia-Pacific to be the Fastest Growing

The share of Asia-Pacific computer-aided drug discovery market is anticipated to grow at a CAGR of 16.4% by registering a revenue of $2,271.4 million by 2028. The growth shall be a result of improvement in healthcare infrastructure and government policies for the use of artificial intelligence for treating various chronic inflammatory diseases such as lupus, rheumatoid arthritis, and more. Increased research activities regarding the target drug development using computer aided drug discovery software is expected to raise the market in the region in the stipulates time period. This substantial growth is attributed to high interest of the scientists and the researchers in the field of bio simulations and 3D drug modelling which will eventually foster the Asia-Pacific computer-aided drug discovery market, in the upcoming years.

Competitive Scenario in the Global Computer-aided Drug Discovery Market

Product launches and mergers & acquisitions are common strategies followed by major market players.

Competitive Scenario in the Global Computer-aided Drug Discovery Market

Source: Research Dive Analysis

Some of the leading computer-aided drug discovery market players are BOCSCI Inc., Bioduro-Sundia, Schrödinger, Inc., Aragen Life Sciences Pvt. Ltd., Aris Pharmaceuticals, Inc, Charles River Laboratories, Bayer AG, AstraZeneca, and Albany Molecular Research Inc. (AMRI).

Porter’s Five Forces Analysis for the Global Computer-aided Drug Discovery Market:

  • Bargaining Power of Suppliers: The service suppliers of computer-aided drug discovery market are high in number and are larger and more globalized. So, there will be less threat from the suppliers.
    Thus, the bargaining power of suppliers is low.  
  • Bargaining Power of Buyers: Buyers demand effective computer-aided drug discovery that can offer best drug discovery. This has increased the pressure on the computer-aided drug discovery providers to offer the best drugs in a cost-effective way. Thus, many suppliers are offering best yet cost –effective computer-aided drug discovery.
    Thus, the bargaining power of the buyers is high. 
  • Threat of New Entrants: Companies entering the computer-aided drug discovery market are adopting various innovations such as developing computer-aided drug discovery that can combine with artificial intelligence and machine learning.
    Thus, the threat of the new entrants is moderate.
  • Threat of Substitutes: There are different types of drug discovery available for treating diseases, but they do not offer the detailed study that computer-aided drug discovery offers.
    Thus, the threat of substitutes is low.
  • Competitive Rivalry in the Market: The competitive rivalry among industry leaders is rather intense, especially between the global players including BOCSCI Inc., Bioduro-Sundia, Schrödinger, Inc. These companies are launching their value-added services in the international market and strengthening the footprint worldwide.
    Therefore, competitive rivalry in the market is high.

Aspect

Particulars

  Historical Market Estimations

  2019-2020

  Base Year for Market Estimation

  2020

  Forecast Timeline for Market Projection

  2021-2028

  Geographical Scope

 North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Type

  • Structure Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

  Segmentation by Therapeutic Area

  • Oncology
  • Neurology
  • Cardiovascular Disease
  • Respiratory Disease
  • Diabetes
  • Others

  Key Companies Profiled

  • BOCSCI Inc.,
  • Bioduro-Sundia,
  • Schrödinger, Inc.,
  • Aragen Life Sciences Pvt. Ltd.,
  • Aris Pharmaceuticals, Inc,
  • Charles River Laboratories,
  • Bayer AG,
  • AstraZeneca,  
  • Albany Molecular Research Inc. (AMRI).

Frequently Asked Questions
 

A. The size of the global computer-aided drug discovery market was over $2,747.1 million in 2020 and is projected to reach $7,914.2 million by 2028.

A. BOCSCI Inc., Bioduro-Sundia and Schrödinger, Inc., are some of the key players in the global computer-aided drug discovery market.

A. The Asia-Pacific region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Asia Pacific computer-aided drug discovery market is anticipated to grow at 16.4% CAGR during the forecast period.

A. Technological development and strategic partnerships are the key strategies opted by the operating companies in this market.

A. Bioduro-Sundia and Schrödinger, Inc., are investing more on R&D activities for developing new products and technologies.

CHAPTER 1:RESEARCH METHODOLOGY

1.1.Desk research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions & forecast parameters

1.4.1.Assumptions
1.4.2.Forecast parameters

CHAPTER 2:EXECUTIVE SUMMARY

2.1.360° summary
2.2.Type trends
2.3.Therapeutic Area trends
2.4.End-user trends

CHAPTER 3:MARKET OVERVIEW

3.1.Market segmentation & definitions
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.2.1.Top winning strategies, by year
3.2.2.2.Top winning strategies, by development
3.2.2.3.Top winning strategies, by company

3.3.Porter’s five forces analysis
3.4.Market dynamics
3.5.Drivers

3.5.1.Rising demand for development of new drugs to boost the market growth
3.5.2.Integration of artificial intelligence for drug discovery may create attractive opportunities for the key players

3.6.Restraints

3.6.1.Lack of skilled technicians for operating computer aided drug discovery software to restrain the market growth

3.7.Opportunities

3.7.1.Advancements in computer-aided drug discovery to create massive investment opportunities

3.8.Regulatory landscape
3.9.Patent landscape
3.10.Technological landscape
3.11.Market value chain analysis
3.12.Strategic Overview

CHAPTER 4:IMPACT OF COVID-19 ON COMPUTER-AIDED DRUG DISCOVERY MARKET

4.1.Introduction
4.2.COVID-19 health assessment
4.3.Impact of COVID-19 on the global economy
4.4.Impact of COVID-19 on global computer aided drug discovery market

4.4.1.Social impact
4.4.2.Technological impact
4.4.3.Investment scenario

4.5.Global Computer-Aided Drug Discovery market size and forecast, by region, 2019-2021

CHAPTER 5:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY TYPE

5.1.Overview

5.1.1.Market size and forecast, by type

5.2.Structure-based Drug Design (SBDD)

5.2.1.Key market trends, growth factors and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market share analysis, by country

5.3.Ligand-based drug design (LBDD)

5.3.1.Key market trends, growth factors and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market share analysis, by country

5.4.Sequence-based approaches

5.4.1.Key market trends, growth factors and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market share analysis, by country

CHAPTER 6:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA

6.1.Overview

6.1.1.Market size and forecast, by therapeutic area

6.2.Oncology

6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market share analysis, by country

6.3.Neurology

6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market share analysis, by country

6.4.Cardiovascular diseases

6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market share analysis, by country

6.5.Respiratory diseases

6.5.1.Key market trends, growth factors and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market share analysis, by country

6.6.Diabetes

6.6.1.Key market trends, growth factors and opportunities
6.6.2.Market size and forecast, by region
6.6.3.Market share analysis, by country

6.7.Others

6.7.1.Key market trends, growth factors and opportunities
6.7.2.Market size and forecast, by region
6.7.3.Market share analysis, by country

CHAPTER 7:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, BY END-USER

7.1.Overview

7.1.1.Market size and forecast, by end-user type

7.2.Pharmaceutical companies

7.2.1.Key market trends, growth factors and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market share analysis, by country

7.3.Biotechnology companies

7.3.1.Key market trends, growth factors and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market share analysis, by country

7.4.Research institutes

7.4.1.Key market trends, growth factors and opportunities
7.4.2.Market size and forecast, by region
7.4.3.Market share analysis, by country

CHAPTER 8:GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast, by region

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by type
8.2.3.Market size and forecast, by therapeutic area
8.2.4.Market size and forecast, by end-user
8.2.5.Market size and forecast, by country
8.2.6.U.S.

8.2.6.1.Market size and forecast, by type
8.2.6.2.Market size and forecast, by therapeutic area type
8.2.6.3.Market size and forecast, by end-user

8.2.7.Canada

8.2.7.1.Market size and forecast, by type
8.2.7.2.Market size and forecast, by therapeutic area type
8.2.7.3.Market size and forecast, by end-user

8.2.8.Mexico

8.2.8.1.Market size and forecast, by type
8.2.8.2.Market size and forecast, by therapeutic area type
8.2.8.3.Market size and forecast, by end-user

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Market size and forecast, by type
8.3.3.Market size and forecast, by therapeutic area type
8.3.4.Market size and forecast, by end-user
8.3.5.Market size and forecast, by country
8.3.6.Germany

8.3.6.1.Market size and forecast, by type

8.3.6.2.Market size and forecast, by therapeutic area type
8.3.6.3.Market size and forecast, by end-user

8.3.7.UK

8.3.7.1.Market size and forecast, by type
8.3.7.2.Market size and forecast, by therapeutic area type
8.3.7.3.Market size and forecast, by end-user

8.3.8.France

8.3.8.1.Market size and forecast, by type
8.3.8.2.Market size and forecast, by therapeutic area type
8.3.8.3.Market size and forecast, by end-user

8.3.9.Spain

8.3.9.1.Market size and forecast, by type
8.3.9.2.Market size and forecast, by therapeutic area type
8.3.9.3.Market size and forecast, by end-user

8.3.10.Italy

8.3.10.1.Market size and forecast, by type
8.3.10.2.Market size and forecast, by therapeutic area type
8.3.10.3.Market size and forecast, by end-user

8.3.11.Rest of Europe

8.3.11.1.Market size and forecast, by type
8.3.11.2.Market size and forecast, by therapeutic area type
8.3.11.3.Market size and forecast, by end-user

8.4.Asia-Pacific

8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Market size and forecast, by type
8.4.3.Market size and forecast, by therapeutic area type
8.4.4.Market size and forecast, by end-user
8.4.5.Market size and forecast, by country
8.4.6.China

8.4.6.1.Market size and forecast, by type
8.4.6.2.Market size and forecast, by therapeutic area type
8.4.6.3.Market size and forecast, by end-user

8.4.7.Japan

8.4.7.1.Market size and forecast, by type
8.4.7.2.Market size and forecast, by therapeutic area type
8.4.7.3.Market size and forecast, by end-user

8.4.8.India

8.4.8.1.Market size and forecast, by type
8.4.8.2.Market size and forecast, by therapeutic area type
8.4.8.3.Market size and forecast, by end-user

8.4.9.South Korea

8.4.9.1.Market size and forecast, by type
8.4.9.2.Market size and forecast, by therapeutic area type
8.4.9.3.Market size and forecast, by end-user

8.4.10.Australia

8.4.10.1.Market size and forecast, by type
8.4.10.2.Market size and forecast, by therapeutic area type
8.4.10.3.Market size and forecast, by end-user

8.4.11.Rest of Asia-Pacific

8.4.11.1.Market size and forecast, by type
8.4.11.2.Market size and forecast, by therapeutic area type
8.4.11.3.Market size and forecast, by end-user

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.2.Market size and forecast, by type
8.5.3.Market size and forecast, by therapeutic area type
8.5.4.Market size and forecast, by end-user
8.5.5.Market size and forecast, by country
8.5.6.Latin America

8.5.6.1.Market size and forecast, by type
8.5.6.2.Market size and forecast, by therapeutic area type
8.5.6.3.Market size and forecast, by end-user

8.5.7.Middle East

8.5.7.1.Market size and forecast, by type
8.5.7.2.Market size and forecast, by therapeutic area type
8.5.7.3.Market size and forecast, by end-user

8.5.8.Africa

8.5.8.1.Market size and forecast, by type
8.5.8.2.Market size and forecast, by therapeutic area type
8.5.8.3.Market size and forecast, by end-user

CHAPTER 9:GLOBAL COMPUTER-AIDED DRUG DISCOVERY MARKET, COMPANY PROFILES

9.1.BOCSCI INC.

9.1.1.Company overview
9.1.2.Product portfolio
9.1.3.Key strategy moves and developments

9.2.BIODURO-SUNDIA

9.2.1.Company overview
9.2.2.Product portfolio
9.2.3.Key strategy moves and developments

9.3.SCHRÖDINGER, INC.

9.3.1.Company overview
9.3.2.Operating business segments
9.3.3.Product portfolio
9.3.4.Business performance
9.3.5.Key strategy moves and developments

9.4.ARAGEN LIFE SCIENCES PVT. LTD.

9.4.1.Company overview
9.4.2.Product portfolio

9.5.ARIS PHARMACEUTICALS, INC.

9.5.1.Company overview
9.5.2.Product portfolio

9.6.CHARLES RIVER LABORATORIES.

9.6.1.Company overview
9.6.2.Operating business segments
9.6.3.Product portfolio
9.6.4.Business performance
9.6.5.Key strategy moves and developments

9.7.BAYER AG

9.7.1.Company overview
9.7.2.Product portfolio
9.7.3.Operating business segments
9.7.4.Business performance
9.7.5.Key strategy moves and developments

9.8.ASTRAZENECA

9.8.1.Company overview
9.8.2.Business performance
9.8.3.Key strategic moves and developments

9.9.ALBANY MOLECULAR RESEARCH INC. (AMRI)

9.9.1.Company overview
9.9.2.Product portfolio
9.9.3.Key strategic moves and developments

9.10.EVOTEC SE

9.10.1.Company overview
9.10.2.Product portfolio
9.10.3.Operating business segments
9.10.4.Business performance
9.10.5.Key strategic moves and developments

Computer-aided drug discovery or CADD is the computational approach for modern discovery of drugs. It includes rational drug design, molecular modeling, computational chemistry, and molecular design. CADD can save a lot of time in drug discovery and is therefore very cost-effective. The demand for rapid drug development for numerous diseases such as cancer is increasing, which is boosting the growth of the global computer-aided drug discovery market.

COVID-19 Impact Analysis

The outbreak of COVID-19 across the globe has progressively impacted the global computer-aided drug discovery (CADD) market, owing to rapid increase in R&D activities among the researchers, scientists, and biopharmaceutical & technological companies in order to curb the spread of the coronavirus disease. Besides, the increasing transmutation rate of COVID-19 has motivated the scientists around the world to discover and develop an effective treatment or drug against the deadly virus. Thus, the importance of research and drug discovery has upsurged, thus boosting the growth of the market.

Moreover, several companies are taking initiatives to sustain and help the society to recover from the chaotic situation with various strategic steps and plans. For instance, in December 2020, BenevolentAI, the UK-based developer of artificial intelligence (AI) and computational medicine technologies, announced that they are developing drugs for COVID-19 treatment with the help of AI and computer-aided drug discovery technology. All these factors are predicted to boost the growth of the global CADD market during the pandemic period.

Key Developments in the Industry

The companies operating in the global industry are adopting various growth strategies and business tactics such as partnerships, business expansion, investments, collaborations, drug development, and drug approvals to obtain a leading position in the global industry, which is predicted to drive the growth of the global computer-aided drug discovery market in upcoming years.

For instance, in February 2021, Optibrium, a leading developer of software for drug discovery, announced to have raised significant investment from a leading UK mid-market private equity firm, Kester Capital, to advance computer-aided drug discovery. The funding will speed-up the development of the business through acquisition and organic growth. Presently, more than 150 organizations across the globe deploy Optibrium’s technology in their research programs.

In June 2021, Mydecine Innovations Group, a biotechnology company in the psychedelics space, announced the launch of virtual drug discovery program that will use machine learning (ML) and artificial intelligence (AI) to inform its drug discovery process.

Forecast Analysis of Global Computer-aided drug discovery Market

The global computer-aided drug discovery market is projected to witness a striking growth during the forecast period, owing to the rising combination of different technologies that speed up the research activities and provides accurate results in short span of time. In addition, the advancements in computer-aided drug discovery is expected to create huge growth opportunities for the global market. Conversely, the lack of technical knowledge and availability of skilled technicians are factors expected to hamper the market growth in the projected timeframe.

The growing usage of artificial intelligence (AI) in drug discovery for drug screening, polypharmacology, chemical synthesis, and to study the three-dimensional (3D) structure of molecules is the significant factor estimated to propel the growth of the global market in the coming future. According to a latest report published by Research Dive, the global computer-aided drug discovery market is expected to garner $7,914.2 million during the forecast period (2021-2028). Regionally, the North America region is estimated to dominate in the global industry, mainly due to increasing and advanced research activities carried out using computer-aided drug discovery in the field of cancer. The key players functioning in the global market include BOCSCI Inc., Schrödinger, Inc., Bioduro-Sundia, Aragen Life Sciences Pvt. Ltd., Charles River Laboratories, Aris Pharmaceuticals, Inc, Bayer AG, Albany Molecular Research Inc. (AMRI), and AstraZeneca.

Purchase Options

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed